Want to see RNLXY full AI Analyst Report?
RNLXY Stock Chart & Stats
$1.85
>-$0.01(-0.27%)
―
--
Day’s Range― - ―
52-Week Range$1.00 - $8.10
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.45K
Market Cap
$15.28M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding8,740,374
10 Day Avg. Volume4,700
30 Day Avg. Volume2,446
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.24
Revenue Forecast (FY)$114.30M
Bulls Say, Bears Say
Bulls Say
Innovative Product OfferingRenalytix's use of machine learning in diagnostics positions it as a leader in innovative kidney disease management, potentially driving long-term growth.
Strategic PartnershipsStrategic collaborations expand market reach and enhance technology adoption, providing diversified revenue streams and long-term business stability.
Revenue ModelThe recurring revenue model from testing fees ensures a steady income stream, supporting financial sustainability and growth potential.
Bears Say
Financial DistressOngoing financial distress with negative equity and losses threatens long-term viability, requiring urgent strategic restructuring for recovery.
Negative Cash FlowNegative cash flow indicates liquidity issues, limiting operational flexibility and the ability to invest in growth opportunities, impacting long-term prospects.
Declining RevenueConsistent revenue decline reflects challenges in market penetration and product adoption, posing risks to sustainable growth and profitability.
Renalytix News
RNLXY FAQ
What was Renalytix’s price range in the past 12 months?
Renalytix lowest stock price was $1.00 and its highest was $8.10 in the past 12 months.
What is Renalytix’s market cap?
Renalytix’s market cap is $15.28M.
When is Renalytix’s upcoming earnings report date?
Renalytix’s upcoming earnings report date is Nov 03, 2026 which is in 107 days.
How were Renalytix’s earnings last quarter?
Renalytix released its earnings results on Mar 26, 2026. The company reported -$1.055 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.055.
Is Renalytix overvalued?
According to Wall Street analysts Renalytix’s price is currently Undervalued.
Does Renalytix pay dividends?
Renalytix does not currently pay dividends.
What is Renalytix’s EPS estimate?
Renalytix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix have?
Renalytix has 8,740,374 shares outstanding.
What happened to Renalytix’s price movement after its last earnings report?
Renalytix reported an EPS of -$1.055 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Renalytix?
Currently, no hedge funds are holding shares in RNLXY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Renalytix
Renalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company's solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.